Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Neeta Bala Tannan, Mandana T. Manzari, Laurie Herviou, Mariana Da Silva Ferreira, Connor Hagen, Hiroto Kiguchi, Katia Manova-Todorova, Venkatraman Seshan, Elisa de Stanchina, Daniel A. Heller, Anas Younes

Blood (2021) 137 (15): 2057–2069.

https://doi.org/10.1182/blood.2020008017

Published: 2021

Includes: Supplemental data

Journal Articles

Dual Inhibition of MCL1 and BCL2 in Lymphoma Using Tumor Targeted Nanoparticles

Neeta Bala Bala, PhD, Mandana Taghizadeh Manzari, PhD, Mariana Da Silva Ferreira, MSc, Zahra Asgari, Connor Hagen, Venkatraman Seshan, PhD, Elisa de Stanchina, Katia Manova-Todorova, Daniel Heller, Anas Younes, MD

Blood (2019) 134 (Supplement_1): 305.

https://doi.org/10.1182/blood-2019-130571

Published: 2019

Journal Articles

Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular structures

Krzysztof Glomski, Sébastien Monette, Katia Manova, Bart De Strooper, Paul Saftig, Carl P. Blobel

Blood (2011) 118 (4): 1163–1174.

https://doi.org/10.1182/blood-2011-04-348557

Published: 2011

Includes: Supplemental data

Journal Articles

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

Luca Paoluzzi, Mithat Gonen, Govind Bhagat, Richard R. Furman, Jeffrey R. Gardner, Luigi Scotto, Volodia D. Gueorguiev, Mark L. Heaney, Katia Manova, Owen A. O'Connor

Blood (2008) 112 (7): 2906–2916.

https://doi.org/10.1182/blood-2007-12-130781

Published: 2008

Journal Articles

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

Luca Paoluzzi, Mithat Gonen, Jeffrey R. Gardner, Jill Mastrella, Dajun Yang, Jon Holmlund, Mel Sorensen, Lance Leopold, Katia Manova, Guido Marcucci, Mark L. Heaney, Owen A. O'Connor

Blood (2008) 111 (11): 5350–5358.

https://doi.org/10.1182/blood-2007-12-129833

Published: 2008

Journal Articles

Role of NPM in the Control of Genetic Stability and Tumorigenesis.

Silvia Grisendi, PhD, Rosa Bernardi, PhD, Marco Rossi, MD, Ke Cheng, BS, Luipa Khandker, BA, Katia Manova, PhD, Pier Paolo Pandolfi, MD/PhD

Blood (2005) 106 (11): 1595.

https://doi.org/10.1182/blood.V106.11.1595.1595

Published: 2005

NARROW

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Dual Inhibition of MCL1 and BCL2 in Lymphoma Using Tumor Targeted Nanoparticles

Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular structures

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

Role of NPM in the Control of Genetic Stability and Tumorigenesis.

Email alerts

ASH Publications

American Society of Hematology

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Dual Inhibition of MCL1 and BCL2 in Lymphoma Using Tumor Targeted Nanoparticles

Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular structures

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

Role of NPM in the Control of Genetic Stability and Tumorigenesis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only